Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis

Clinical Immunology

Volumn 179, Issue , 2017, Pages 8-16

  Merlo, Lauren M F ^a   Grabler, Samantha ^a   DuHadaway, James B ^a   Pigott, Elizabeth ^a   Manley, Kaylend ^a   Prendergast, George C ^a,b,c   Laury Kleintop, Lisa D ^a   Mandik Nayak, Laura ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antibody therapy; B cells; Experimental arthritis; IDO; Murine model

Indexed keywords

FC RECEPTOR IIB; IMMUNOGLOBULIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 21; MONOCLONAL ANTIBODY; MONOCLONAL INDOLEAMINE 2,3 DIOXYGENASE IMMUNOGLOBULIN; UNCLASSIFIED DRUG; FC RECEPTOR; FCGR2B PROTEIN, MOUSE; IDO2 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LIVER TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; B LYMPHOCYTE; C57BL MOUSE; CHEMICALLY INDUCED; CYTOLOGY; DBA MOUSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPH NODE; PATHOLOGY; SPLEEN; T LYMPHOCYTE; TARSAL JOINT;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; FEMALE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPH NODES; MALE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; RECEPTORS, IGG; SPLEEN; T-LYMPHOCYTES; TARSAL JOINTS;

EID: 85014037152     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2017.01.016     Document Type: Article

References (81)

1. [1] Helmick, C.G., Felson, D.T., Lawrence, R.C., Gabriel, S., Hirsch, R., Kwoh, C.K., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58 (2008), 15–25.
2. [2] Gibofsky, A., Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis. Am. J. Manag. Care 20 (2014), s128–s145.
3. [3] Curtis, J.R., Singh, J.A., Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin. Ther. 33 (2011), 679–707.
4. [4] Singh, J.A., Furst, D.E., Bharat, A., Curtis, J.R., Kavanaugh, A.F., Kremer, J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 64 (2012), 625–639.
5. [5] Alghasham, A., Rasheed, Z., Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity 47 (2014), 77–94.
6. [6] Tian, H., Cronstein, B.N., Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull. NYU Hosp. Jt Dis. 65 (2007), 168–173.
7. [7] Albrecht, K., Muller-Ladner, U., Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin. Exp. Rheumatol. 28 (2010), S95–101.
8. [8] Buch, M.H., Smolen, J.S., Betteridge, N., Breedveld, F.C., Burmester, G., Dorner, T., et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70 (2011), 909–920.
9. [9] Cooper, N., Arnold, D.M., The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br. J. Haematol. 149 (2010), 3–13.
10. [10] Solomon, D.H., Kremer, J.M., Fisher, M., Curtis, J.R., Furer, V., Harrold, L.R., et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin. Arthritis Rheum. 43 (2014), 489–497.
11. [11] Curtis, J.R., Yang, S., Patkar, N.M., Chen, L., Singh, J.A., Cannon, G.W., et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res. 66 (2014), 990–997.
12. [12] Pigott, E., Duhadaway, J.B., Muller, A.J., Gilmour, S., Prendergast, G.C., Mandik-Nayak, L., 1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity 47 (2014), 409–418.
13. [13] Pigott, E., Mandik-Nayak, L., Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice. Arthritis Rheum. 64 (2012), 2169–2178.
14. [14] Muller, A.J., Mandik-Nayak, L., Prendergast, G.C., Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy 2 (2010), 293–297.
15. [15] Merlo, L.M., Pigott, E., Duhadaway, J.B., Grabler, S., Metz, R., Prendergast, G.C., et al. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J. Immunol. 192 (2014), 2082–2090.
16. [16] Merlo, L.M., DuHadaway, J., Grabler, S., Prendergast, G.C., Muller, A.J., Mandik-Nayak, L., IDO2 modulates T cell-dependent autoimmune responses through a B cell-intrinsic mechanism. J. Immunol. 196 (2016), 4487–4497.
17. [17] Scott, G.N., DuHadaway, J., Pigott, E., Ridge, N., Prendergast, G.C., Muller, A.J., et al. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J. Immunol. 182 (2009), 7509–7517.
18. [18] Prendergast, G.C., Metz, R., Muller, A.J., Merlo, L.M., Mandik-Nayak, L., IDO2 in immunomodulation and autoimmune disease. Front. Immunol., 5, 2014, 585.
19. [19] Taylor, M.W., Feng, G.S., Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5 (1991), 2516–2522.
20. [20] Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998), 1191–1193.
21. [21] Elovainio, M., Hurme, M., Jokela, M., Pulkki-Raback, L., Kivimaki, M., Hintsanen, M., et al. Indoleamine 2,3-dioxygenase activation and depressive symptoms: results from the Young Finns Study. Psychosom. Med. 74 (2012), 675–681.
22. [22] Oxenkrug, G.F., Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr. J. Psychiatry Relat. Sci. 47 (2010), 56–63.
23. [23] Xiao, Y., Christou, H., Liu, L., Visner, G., Mitsialis, S.A., Kourembanas, S., et al. Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 188 (2013), 482–491.
24. [24] Prendergast, G.C., Chang, M.Y., Mandik-Nayak, L., Metz, R., Muller, A.J., Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr. Med. Chem. 18 (2011), 2257–2262.
25. [25] Muller, A.J., Scherle, P.A., Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer 6 (2006), 613–625.
26. [26] Schroecksnadel, K., Winkler, C., Duftner, C., Wirleitner, B., Schirmer, M., Fuchs, D., Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin. Rheumatol. 25 (2006), 334–337.
27. [27] Pertovaara, M., Hasan, T., Raitala, A., Oja, S.S., Yli-Kerttula, U., Korpela, M., et al. Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin. Exp. Immunol. 150 (2007), 274–278.
28. [28] Furuzawa-Carballeda, J., Lima, G., Jakez-Ocampo, J., Llorente, L., Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study. Eur. J. Clin. Investig. 41 (2011), 1037–1046.
29. [29] Gurtner, G.J., Newberry, R.D., Schloemann, S.R., McDonald, K.G., Stenson, W.F., Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 125 (2003), 1762–1773.
30. [30] Sakurai, K., Zou, J.P., Tschetter, J.R., Ward, J.M., Shearer, G.M., Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129 (2002), 186–196.
31. [31] Szanto, S., Koreny, T., Mikecz, K., Glant, T.T., Szekanecz, Z., Varga, J., Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res. Ther., 9, 2007, R50.
32. [32] Fallarino, F., Volpi, C., Zelante, T., Vacca, C., Calvitti, M., Fioretti, M.C., et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J. Immunol. 183 (2009), 6303–6312.
33. [33] Xu, H., Oriss, T.B., Fei, M., Henry, A.C., Melgert, B.N., Chen, L., et al. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 6690–6695.
34. [34] von Bubnoff, D., Bieber, T., The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy. Allergy 67 (2012), 718–725.
35. [35] Metz, R., Smith, C., DuHadaway, J.B., Chandler, P., Baban, B., Merlo, L.M.F., et al. IDO2 is critical for IDO1-mediated T cell regulation and exerts a non-redundant function in inflammation. Int. Immunol. 26 (2014), 357–367.
36. [36] Metz, R., Rust, S., Duhadaway, J.B., Mautino, M.R., Munn, D.H., Vahanian, N.N., et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 1 (2012), 1460–1468.
37. [37] Ravishankar, B., Liu, H., Shinde, R., Chandler, P., Baban, B., Tanaka, M., et al. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 3909–3914.
38. [38] Put, K., Brisse, E., Avau, A., Imbrechts, M., Mitera, T., Janssens, R., et al. IDO1 deficiency does not affect disease in mouse models of systemic juvenile idiopathic arthritis and secondary hemophagocytic lymphohistiocytosis. PLoS One, 11, 2016, e0150075.
39. [39] Imai, K., Takaoka, A., Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6 (2006), 714–727.
40. [40] Townsend, M.J., Monroe, J.G., Chan, A.C., B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev. 237 (2010), 264–283.
41. [41] Cantini, F., Niccoli, L., Nannini, C., Cassara, E., Kaloudi, O., Giulio Favalli, E., et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin. Arthritis Rheum. 45 (2016), 519–532.
42. [42] Dinarello, C.A., Joosten, L.A., Inflammation in rheumatology in 2015: new tools to tackle inflammatory arthritis. Nat. Rev. Rheumatol. 12 (2016), 78–80.
43. [43] Kamenarska, Z.G., Hristova, M.H., Vinkov, A.I., Dourmishev, L.A., Monoclonal antibody drugs for systemic lupus erythematosus. Folia Med. 57 (2015), 89–92.
44. [44] Milo, R., Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun. Rev. 15 (2016), 714–718.
45. [45] Safdari, Y., Ahmadzadeh, V., Farajnia, S., CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. Investig. New Drugs 34 (2016), 497–512.
46. [46] Nimmerjahn, F., Ravetch, J.V., Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun., 12, 2012, 13.
47. [47] Tsirigotis, P., Savani, B.N., Nagler, A., Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. Ann. Med., 2016, 1–12.
48. [48] Farkona, S., Diamandis, E.P., Blasutig, I.M., Cancer immunotherapy: the beginning of the end of cancer?. BMC Med., 14, 2016, 73.
49. [49] Guo, K., Li, J., Tang, J.P., Tan, C.P., Hong, C.W., Al-Aidaroos, A.Q., et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci. Transl. Med., 3, 2011, 99ra85.
50. [50] Noble, P.W., Chan, G., Young, M.R., Weisbart, R.H., Hansen, J.E., Optimizing a lupus autoantibody for targeted cancer therapy. Cancer Res. 75 (2015), 2285–2291.
51. [51] Dao, T., Yan, S., Veomett, N., Pankov, D., Zhou, L., Korontsvit, T., et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci. Transl. Med., 5, 2013, 176ra33.
52. [52] Gondi, G., Mysliwietz, J., Hulikova, A., Jen, J.P., Swietach, P., Kremmer, E., et al. Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res. 73 (2013), 6494–6503.
53. [53] Brand, D.D., Latham, K.A., Rosloniec, E.F., Collagen-induced arthritis. Nat. Protoc. 2 (2007), 1269–1275.
54. [54] Seo, S.K., Choi, J.H., Kim, Y.H., Kang, W.J., Park, H.Y., Suh, J.H., et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10 (2004), 1088–1094.
55. [55] Criado, G., Simelyte, E., Inglis, J.J., Essex, D., Williams, R.O., Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. Arthritis Rheum. 60 (2009), 1342–1351.
56. [56] Krebs, C.F., Steinmetz, O.M., CD4 + T cell fate in glomerulonephritis: a tale of Th1, Th17, and novel Treg subtypes. Mediat. Inflamm., 2016, 2016, 5393894.
57. [57] Ettinger, R., Kuchen, S., Lipsky, P.E., The role of IL-21 in regulating B-cell function in health and disease. Immunol. Rev. 223 (2008), 60–86.
58. [58] Jang, E., Cho, S.H., Park, H., Paik, D.J., Kim, J.M., Youn, J., A positive feedback loop of IL-21 signaling provoked by homeostatic CD4 + CD25- T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice. J. Immunol. 182 (2009), 4649–4656.
59. [59] Nimmerjahn, F., Ravetch, J.V., Fcgamma receptors as regulators of immune responses. Nat. Rev. 8 (2008), 34–47.
60. [60] Takai, T., Li, M., Sylvestre, D., Clynes, R., Ravetch, J.V., FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76 (1994), 519–529.
61. [61] Amigorena, S., Bonnerot, C., Drake, J.R., Choquet, D., Hunziker, W., Guillet, J.G., et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256 (1992), 1808–1812.
62. [62] Muta, T., Kurosaki, T., Misulovin, Z., Sanchez, M., Nussenzweig, M.C., Ravetch, J.V., A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature, 369, 1994, 340.
63. [63] Williams, E.L., Tutt, A.L., French, R.R., Chan, H.T., Lau, B., Penfold, C.A., et al. Development and characterisation of monoclonal antibodies specific for the murine inhibitory Fc gamma RIIB (CD32B). Eur. J. Immunol. 42 (2012), 2109–2120.
64. [64] LaBranche, T.P., Hickman-Brecks, C.L., Meyer, D.M., Storer, C.E., Jesson, M.I., Shevlin, K.M., et al. Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse. Am. J. Pathol. 177 (2010), 1388–1396.
65. [65] Soliman, H., Mediavilla-Varela, M., Antonia, S., Indoleamine 2,3-dioxygenase: is it an immune suppressor?. Cancer J. 16 (2010), 354–359.
66. [66] Soliman, H.H., Antonia, S., Sullivan, D., Vanahanian, N., Link, C., Overcoming tumor antigen anergy in human malignancies using the novel indoleamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J. Clin. Oncol., 27, 2009 (Abstract 3004).
67. [67] Soliman, H.H., Minton, S.E., Han, H.S., Ismail-Khan, R., Mahipal, A., Janssen, W., et al. A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. J. Clin. Oncol., 2013 (suppl abstract 3069).
68. [68] Soliman, H.H., Jackson, E., Neuger, T., Dees, E.C., Harvey, R.D., Han, H., et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 5 (2014), 8136–8146.
69. [69] Austin, C.J., Mailu, B.M., Maghzal, G.J., Sanchez-Perez, A., Rahlfs, S., Zocher, K., et al. Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2. Amino Acids 39 (2010), 565–578.
70. [70] Bakmiwewa, S.M., Fatokun, A.A., Tran, A., Payne, R.J., Hunt, N.H., Ball, H.J., Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2. Bioorg. Med. Chem. Lett. 22 (2012), 7641–7646.
71. [71] Wang, D., Li, Y., Liu, Y., Shi, G., The use of biologic therapies in the treatment of rheumatoid arthritis. Curr. Pharm. Biotechnol. 15 (2014), 542–548.
72. [72] Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54 (2006), 2793–2806.
73. [73] Lipsky, P.E., van der Heijde, D.M., St Clair, E.W., Furst, D.E., Breedveld, F.C., Kalden, J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343 (2000), 1594–1602.
74. [74] Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Davis, D., Macfarlane, J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41 (1998), 1552–1563.
75. [75] Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994), 1105–1110.
76. [76] Guo, K., Tang, J.P., Tan, C.P., Wang, H., Zeng, Q., Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol. Ther. 7 (2008), 750–757.
77. [77] Haynes, N.M., Hawkins, E.D., Li, M., McLaughlin, N.M., Hammerling, G.J., Schwendener, R., et al. CD11c + dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J. Immunol. 185 (2010), 532–541.
78. [78] Li, F., Ravetch, J.V., Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333 (2011), 1030–1034.
79. [79] White, A.L., Chan, H.T., Roghanian, A., French, R.R., Mockridge, C.I., Tutt, A.L., et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187 (2011), 1754–1763.
80. [80] Lim, S.H., Vaughan, A.T., Ashton-Key, M., Williams, E.L., Dixon, S.V., Chan, H.T., et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118 (2011), 2530–2540.
81. [81] Beers, S.A., French, R.R., Chan, H.T., Lim, S.H., Jarrett, T.C., Vidal, R.M., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115 (2010), 5191–5201.